Beyond Journal Club Podcast from Core IM

Published October 4, 2023

What is the difference between semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) in metabolic outcomes and mechanism? How did we find out diabetes medications can help with weight loss? SURMOUNT-1 asked the question, "Does tirzepatide, a once weekly injectable drug used for diabetes, help patients lose weight compared to placebo?" What impact might the results have on contemporary medicine? To find out, listen to the second episode in this new series brought to you by Core IM in collaboration with NEJM Group.

02:08 – Framework for thinking about obesity
03:42 – History of obesity treatment
06:29 – Gila monsters and GLP and GIP mechanisms
08:29 – Story of how medications for diabetes were found to have a weight loss benefit
12:50 – SURMOUNT-1 trial

Read the Show Notes and learn more about Core IM.

View the episode transcript and references.

Review the relevant sections on Obesity in the Adult Endocrinology guide in Rotation Prep.

Beyond Journal Club is a new collaboration between Core IM and NEJM Group where we put the results of clinical trials into context. We tell the story of how we arrived at the current standard of care, appreciate the clinical question of the trial at hand, and interpret what the findings may mean for this patient population.